Washington, D.C. – October 1, 2026 – Commitment to Seniors (C2S), a project of American Commitment, opposes the final rule for the Global Benchmark for Efficient Drug Pricing (GLOBE) model from the Centers for Medicare and Medicaid Innovation (CMMI).
This model effectively imposes price controls on the American health care market by tying U.S. drug prices to prices set by foreign governments. Importing foreign price controls risks American jobs, undermines U.S. leadership in pharmaceutical innovation, and could cede further ground to China as it continues to invest heavily in biotechnology. This policy could also jeopardize investment in breakthrough therapies for illnesses and conditions that disproportionately affect seniors, including cancer, Alzheimer’s disease, and other chronic illnesses.
Addressing foreign freeloading must be a priority, but the GLOBE model is the wrong solution to that problem. Instead, President Trump should use bold trade negotiations to press other wealthy nations to pay their fair share for medical innovation, just as he successfully pushed NATO allies to increase their defense spending.
“The final rule for the GLOBE model is the wrong approach to addressing rising health care costs and ending foreign freeloading,” said Phil Kerpen, President of American Commitment. “To lower costs while protecting innovation, the administration must champion free-market policies that expand patient choice, promote competition, and require transparency, while pushing other wealthy nations to pay their fair share.”